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ABSTRACT
We have previously demonstrated inverse associations betweenmaternal 25(OH)-vitamin D status and perinatal DNAmethylation at the
retinoid-X-receptor-alpha (RXRA) locus and between RXRA methylation and offspring bone mass. In this study, we used an existing
randomized trial to test the hypothesis thatmaternal gestational vitamin D supplementationwould lead to reduced perinatal RXRA locus
DNA methylation. The Maternal Vitamin D Osteoporosis Study (MAVIDOS) was a multicenter, double-blind, randomized, placebo-
controlled trial of 1000 IU/day cholecalciferol ormatched placebo from14weeks’ gestation until delivery. Umbilical cord (fetal) tissuewas
collected at birth and frozen at80°C (n¼ 453). Pyrosequencingwas used to undertake DNAmethylation analysis at 10 CpG sites within
the RXRA locus (identiﬁed previously). T tests were used to assess differences between treatment groups inmethylation at the threemost
representative CpG sites. Overall, methylation levels were signiﬁcantly lower in the umbilical cord from offspring of cholecalciferol-
supplemented mothers, reaching statistical signiﬁcance at four CpG sites, represented by CpG5: mean difference in % methylation
between the supplementedandplacebogroupswas1.98% (95%CI,3.65 to0.32,p¼ 0.02). ENCODE (EncyclopediaofDNAElements)
evidence supports the functionality of this locus with strong DNase hypersensitivity and enhancer chromatin within biologically relevant
cell types including osteoblasts. Enrichment of the enhancer-relatedH3K4me1 histonemark is also seen in this region, as are binding sites
for a range of transcription factors with roles in cell proliferation, response to stress, and growth factors. Our ﬁndings are consistent with
previous observational results and provide new evidence thatmaternal gestational supplementationwith cholecalciferol leads to altered
perinatal epigenetic marking, informing mechanistic understanding of early life mechanisms related to maternal vitamin D status,
epigenetic marks, and bone development. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
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Introduction
It is becoming increasingly recognized that environmentalfactors acting through epigenetic mechanisms induce persis-
tent changes in gene expression, leading to differences in
phenotype.(1,2) Various examples of such epigenetic mecha-
nisms have come from the natural world, and also from
experimental animal studies. For example, altered pregnancy
diet in rats has been shown to lead to modiﬁcation of DNA
methylation, gene expression, and phenotype in the
offspring.(1–4) Evidence for the relevance of such mechanisms
in human disease is increasing; we have recently documented
associations between perinatal DNA methylation at particular
loci and bone phenotype in the offspring.(5,6) We previously
demonstrated that methylation at the cyclin-dependent kinase
inhibitor 2A (CDKN2A)(6) and retinoid-X-receptor-alpha (RXRA)(5)
loci in umbilical cord DNA was associated with offspring bone
mass in childhood in the Southampton Women’s Survey (SWS)
mother–offspring cohort. RXRA is an essential part of vitamin D
signaling, forming a heterodimer with the vitamin D receptor in
the nuclear action of 1,25(OH)2-vitamin D. We reasoned that this
latter observation might be of key relevance to our demon-
strations of associations between maternal 25(OH)-vitamin D
status in pregnancy and offspring bone mass,(7–9) together with
our ﬁnding of a positive effect of maternal vitamin D
supplementation during pregnancy on neonatal bone mass
for winter births (when background 25(OH)-vitamin D concen-
trations are lowest).(10) In the SWS, methylation at one CpG site
upstream of the RXRA promoter was associated with a marker of
maternal pregnancy 25(OH)-vitamin D status, with greater 25
(OH)-vitamin D status associated with lower RXRA promoter
methylation.(5) Clearly, causation cannot be concluded from an
observational study; therefore, we hypothesized, in the setting
of the Maternal Vitamin D Osteoporosis Study (MAVIDOS)
randomized, double-blind, placebo-controlled trial of vitamin D
supplementation in pregnancy,(10) that this intervention would
lead to reduced RXRA DNA methylation in umbilical cord tissue
at birth compared with placebo.
Participants and Methods
Participants: The Maternal Vitamin D Osteoporosis Study
We analyzed RXRA DNA methylation data from the MAVIDOS
study, a multicenter, double-blind, randomized, placebo-
controlled trial of vitamin D supplementation in pregnancy, in
which the primary outcome was neonatal bone mass. The study
methods and primary ﬁndings have been published previ-
ously.(10,11) The study was approved by the Southampton and
South West Hampshire Research Ethics Committee. MAVIDOS
was registered prospectively (International Standard Random-
ised Controlled Trial Registry: ISRCTN 82927713; European
Clinical Trials Database: EudraCT 2007-001716-23) with full
approval from the UK Medicines and Healthcare Products
Regulatory Agency. Written informed consent was obtained
from all participants.
Women attending one of three UK hospitals (University
Hospital Southampton NHS Foundation Trust, Southampton;
Oxford University Hospitals NHS Foundation Trust, Oxford;
Shefﬁeld Hospitals NHS Trust, University of Shefﬁeld, Shefﬁeld)
for early pregnancy ultrasound screening (11 to 14 weeks’
gestation) between October 6, 2008 and February 11, 2014 were
invited to participate in the study.(10,11) Inclusion criteria were
age over 18 years, singleton pregnancy, and gestation less than
17 weeks based on last menstrual period and ultrasound
measurements. Exclusion criteria included women with known
metabolic bone disease, renal stones, hyperparathyroidism or
hypercalciuria, those taking medication known to interfere with
fetal growth, fetal anomalies on ultrasonography, and women
already using >400 IU/day vitamin D supplementation. A
screening blood sample was obtained and analyzed on the local
NHS platform [all three hospitals participate in the DEQAS
(Vitamin D External Quality Assessment Scheme); http://www.
deqas.org/]; women with 25(OH)D between 25 and 100 nmol/L
and serum calcium <2.75mmol/L were eligible to enroll in the
study.
Participants were randomized to receive either cholecalciferol
1000 IU/day or matched placebo [Merck KGaA, Darmstadt,
Germany)/Sharp Clinical Services (previously DHP-Bilcare),
Crickhowell, UK], from before 17 weeks’ gestation until delivery.
Packs of study treatment were randomly assigned in a 1:1 ratio
by Sharp Clinical Services using a computer-generated
sequence in randomly permuted blocks of 10, starting randomly
midway through the block, and sequentially numbered, before
delivery to the study sites, and then were dispensed in order by
each study pharmacist. The study medication was provided in a
blister pack in a single box containing all medication for the
whole pregnancy. The participants, those providing antenatal
and intrapartum care, and all ﬁeld researchers involved in data
collection and sample analysis were blinded to the intervention.
All participants received standard antenatal care, and could
continue self-administration of dietary supplements containing
up to 400 IU/day vitamin D.
Maternal assessments during pregnancy
The participants attended the research center for a detailed
assessment of diet (including supplement use), lifestyle (smoking,
physical activity participation, employment), and health (past
medical history, current medication use) using interviewer-led
questionnaires both prior to commencing the study medication,
and again at 34-weeks’ gestation. Ethnicity was reported by the
participant and categorized as white or non-white.
Assessment of 25(OH)D status
A nonfasted venous blood sample was obtained on the day that
the study medication was dispensed and also at 34-weeks’
gestation; serum was stored at80°C. 25(OH)D was assessed by
chemiluminescent assay (liaison automated platform; DiaSorin,
Stillwater, MN, USA). All samples were analyzed in a single batch
at the end of the study at MRC Human Nutrition Research,
Cambridge, UK. Details of assay performance and quality control
through participation in the DEQAS, US National Institute of
Standards and Technology (NIST), and the UK National External
Quality Assessment Service (NEQAS) are given elsewhere.(12,13)
Neonatal DXA
All neonates underwent DXA assessment at whole-body minus
head and lumbar spine sites (Hologic Discovery, Hologic Inc,
Bedford, MA, USA, or GE-Lunar iDXA, GE-Lunar, Madison, WI, USA,
with neonatal software) within 2 weeks of birth. The current
analysis uses thewhole-bodyminusheadmeasures. The infantwas
undressed, clothed in a standard towel, fed, andpaciﬁedbefore the
assessment. Each instrument underwent daily quality control with
cross-calibration between sites. The total radiation dose was
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estimated tobe 0  04mSv, equivalent to about 7-days’ exposure to
background radiation in the UK. All DXA images were reviewed for
movement artifacts and quality by two operators (NCH and RJM),
who were blinded to treatment allocation.
Umbilical cord DNA extraction
Immediately following delivery, a 5- to 10-cm segment was cut
from the midportion of each cord, ﬂushed with saline to remove
fetalblood,ﬂash-frozen in liquidnitrogen, andstoredat80°Cuntil
required for DNA isolation. Genomic DNAwas isolated from frozen
archived umbilical cord tissue by classical proteinase K digestion
and phenol:chloroform extraction.
Quantitative DNA methylation analysis and
pyrosequencing
The region of interest is in close proximity of the RXRA gene
locus, 2252 base pairs upstream from the transcriptional start
site. It contains 12 CpG dinucleotides (chr9: 137215735 to
137216064, human genome hg19/GRCh37 build; Supplemen-
tary Fig. 1). We used sodium bisulﬁte targeted pyrosequencing
(Pyromark MD; QIAGEN, Hilden, Germany; https://www.qiagen.
com/ﬁ/resources/technologies/pyrosequencing-resource-
center/technology-overview/)(14) to carry out in-depth analysis
of the methylation status of 10 out of 12 CpGs within the
previously identiﬁed differentially methylated region of RXRA in
umbilical cords. Pyrosequencing was not performed on CpG 6
and CpG 7 [at genomic coordinates (hg19) chr9 137215867 and
137215956, respectively] for sample conservation purposes
because of their distance from other CpGs (therefore requiring
separate amplicons), as shown in Supplementary Fig. 1. Inter-
and intraplate controls were added to each plate as a control for
inter- and intraplate variability, and 0% and 100% methylation
controls were run to ensure that the full range of methylation
could be detected. The genomic coordinates for the RXRA CpG
sites are provided in Supplementary Table 1.
Statistical analysis
Womenwho had delivered a liveborn infant and babies who had
umbilical cord RXRA pyrosequencing analysis were included in
the analysis. All outcomes were assessed for normality via visual
inspection of histograms. Percentage DNA methylation at all
RXRA CpGs analyzed was normally distributed, except at CpG 1
and CpG 3. Characteristics of the women in the two treatment
arms were compared using t tests, and Mann-Whitney U and x2
tests for normally distributed, non-normally distributed, and
categorical variables, respectively. Characteristics of the MAVI-
DOS babies (boys versus girls) for whomneonatal DXA and RXRA
methylation data were available were also compared. Neonatal
DXA indices were whole-body minus head bone area (BA), BMC,
and areal bone mineral density (aBMD). Continuous child
characteristics were summarized using mean (SD) or median
(interquartile range [IQR]). Categorical variables were summa-
rized using percentages. Differences in continuous variables
between boys and girls were tested using t tests or Mann-
Whitney U tests where appropriate. All participants were
analyzed by the group to which they were originally random-
ized. Differences in RXRA DNA methylation between the two
treatment groupswere compared using t tests orMann-Whitney
U tests for normally distributed and non-normally distributed
variables, respectively. RXRA methylation was Fisher-Yates
transformed to SDs. Separate linear regression analyses were
carried out to analyze the difference inmethylation between the
treatment groups. We analyzed the interaction between
treatment group, RXRAmethylation, and season of birth because
of previously described seasonal variations in 25(OH)D concen-
trations reported in many previous studies. To ensure adequate
sample sizes, we deﬁned season of birth as a binary variable
using the UK Meteorological Ofﬁce classiﬁcation, combining
winter (December to February) with spring (March to May) to
give an overall “winter” variable (December to May), and
summer (June to August) with autumn (September to Novem-
ber) to give an overall “summer” variable (June to November). To
explore associations between RXRA methylation and bone
outcomes, linear regression analyses were carried out, adjusted
for treatment group and sex where appropriate.
Based on previous ﬁndings, we recognized that there was
likely to be colinearity between the individual exposures and
outcomes,(5,6) so we undertook a data reduction approach by
investigating clustering of the CpG methylation.(6) Our approach
was appropriate given the relatively small number of tests in our
analysis, compared with larger scale genome-wide associations
studies, for which methods such as Bonferroni or the Benjamini-
Hochberg/false discovery rate corrections for multiple testing
wouldbeappropriate.(15) Previous studieshave shown thatwhere
clusters of differential CpGs can be identiﬁed, they aremore likely
to be of functional relevance than are individual CpG changes.(16)
By investigating the correlation between methylation at each of
the individual CpG sites (Supplementary Table 2) and calculating
the median absolute deviation (MAD) from the median for each
site (Supplementary Table 3),wegrouped theCpGsites into three
clusters (CpG 1 to CpG 5, CpG 8 to CpG 11, CpG 12), with each
cluster represented by the sitewith thehighestMADscore (ie, the
sitewith thegreatest variabilitywithin the cluster): CpG sites 5, 11,
and 12, respectively. For completeness, we also used the Simes’
modiﬁcation of the Bonferroni method to undertake a p-value
correction on the analyses, using the Stata “qqvalue” command
(StataCorp, College Station, TX, USA), which is similar to the “p.
adjust” command in R https://www.rdocumentation.org/
packages/stats/versions/3.1.1/topics/p.adjust. These are pre-
sented as q values in the relevant results Tables 2, 3 and
Supplementary Table 4.
Further biological support for this clustering was provided by
exploration of the ENCODE data,(17) demonstrating distinct
DNase I hypersensitivity sites at either end of the differentially
methylated region, and discrete grouping of transcription factor
binding. All analyses were performed in Stata v14 (StataCorp). A
p value of <0.05 was considered statistically signiﬁcant.
Results
Characteristics of participants
There were 965 women (85%) who remained in the study until
delivery (Fig. 1).(10) There were 486 live births in the control group
and 479 in the cholecalciferol group, of which 228 and 225
umbilical cords, respectively, underwent pyrosequencing of the
RXRA region of interest. Seventy-eight babies for whom
pyrosequencing results were available did not have a useable
DXA scan (43 randomized to placebo, 35 to cholecalciferol),
leaving 375 babies with RXRA methylation analyses, DXA
outcomes, and the relevant maternal information. Of the 453
women included in the initial analysis, the mean age at delivery
was 30.9 (SD 5.2) years in the placebo group and 30.7 (SD 5.1)
years in the cholecalciferol supplemented group. Baseline
characteristics of women in the placebo and cholecalciferol
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groups at randomization were similar (Table 1A). Neonatal DXA
whole-body minus head bone measurements were available for
202 boys (91 born to mothers randomized to placebo, 111 to
cholecalciferol) and 173 girls (94 born to mothers randomized to
placebo, 79 to cholecalciferol; Table 1B). A x2 test demonstrated
no difference in the sex distribution of the treatment groups.
There was no difference in gestational age between the boys and
girls. As would be expected, boys had a greater average whole-
body minus head bone mineral content (g) and bone area (cm2)
than girls. In this subset of the MAVIDOS trial population, no
differences in gestational age or whole-body minus head DXA
outcomes were observed in the babies by maternal randomiza-
tion group to placebo or 1000 IU cholecalciferol (Table 1C).
Cholecalciferol supplementation and perinatal RXRA
methylation
Percentage methylation at the RXRA differentially methylated
region (DMR) varied greatly across the 10 CpG sites measured,
for example, ranging from 29.0% to 81.4% at CpG 5 (mean
47.7%, SD 9.0%; Supplementary Table 1). However, percentage
methylation tended to be lower in the cholecalciferol-supple-
mented group than in the placebo group (Fig. 2). At CpG 5
(representing CpG 1 to CpG 5), mean (SD) percentage
methylation was 46.7% (8.2%) in the cholecalciferol group
and 48.7% (9.7%) in the placebo group (mean difference 1.98
percentage points, p¼ 0.02). Although percentage methylation
at both CpG 11 (representing CpG 8 to CpG 11) and CpG 12 was
lower in cholecalciferol than placebo group births, these
differences were not statistically signiﬁcant (Table 2 and
Supplementary Table 4). We observed no consistent associa-
tions between maternal 25(OH)D status at 34 weeks, or change
in 25(OH)D from early to late pregnancy, and RXRA methylation
in umbilical cord tissue across the cohort. However, there was
evidence of an interaction between change in 25(OH)D between
14- and 34-weeks’ gestation 25(OH)D and treatment allocation
to cholecalciferol or placebo on RXRA methylation at CpG 11
(p¼ 0.022).
Interactions between season of birth, treatment group,
and percentage DNA methylation at RXRA
Greater increases in maternal 25(OH)D status were seen in
summer (June to November) than in winter (December to May)
births; the increase in 25(OH)D during pregnancy wasmore than
double in the women giving birth in summer. In summer births,
mean (SD) change in 25(OH)D between 14- and 34-weeks’
gestation was 8.1 (16.0) nmol/L in the placebo group (n¼ 124),
and 28.0 (19.8) nmol/L in the vitamin D supplemented group
(n¼ 127). In winter births, mean (SD) change in 25(OH)D
Fig. 1. MAVIDOS trial consort diagram.
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between 14- and 34-weeks’ gestationwas15.0 (17.6) nmol/L in
the placebo group (n¼ 103), and 13.6 (22.6) nmol/L in the
vitamin D supplemented group (n¼ 95).
There was evidence of statistically signiﬁcant interactions for
the outcome of RXRAmethylation between treatment allocation
(cholecalciferol versus placebo) and season of birth (at all three
representative CpGs: CpG 5, p¼ 0.02; CpG 11, p¼ 0.009; and
CpG 12 p¼ 0.01). The effect of treatment group on RXRA
methylation appeared greater in summer than winter births
(Table 3). In summer births, there was a difference in percentage
methylation at RXRA CpG 5, CpG 11, and CpG 12 between
treatment groups ranging from 3.69% at CpG 5 (p¼ 0.001), to
2.38% at CpG 11 (p¼ 0.01), and 2.13% at CpG 12 (p¼ 0.005),
but the differences between groups were nonsigniﬁcant for
winter births. This interaction persisted after adjustment for
potential differences in maternal characteristics between the
season groups (maternal BMI and skinfold thickness), and for
other factors known to inﬂuence methylation (offspring sex and
maternal smoking).
RXRA methylation and offspring bone indices measured
by DXA
In the population as a whole, there were modest positive
associations between RXRA methylation at CpG 5 and offspring
whole-body minus head BA, BMC, and aBMD (Table 4). However,
on stratiﬁcation according to treatment allocation, associations
were noted in the placebo, but not the cholecalciferol
Table 1A. Baseline Characteristics of the Randomly Assigned Pregnant Women Included in the Analysis
n Placebo (N¼ 228) Cholecalciferol 1000 IU/day (N¼ 225)
Mean (SD) or median (IQR)
Age (years) 427 30.9 (5.2) 30.7 (5.1)
Height (cm) 423 166.4 (6.3) 165.3 (6.1)
Weight (kg) 427 73.6 (13.1) 71.6 (14.1)
Pregnancy weight gain (kg) 415 9.4 (3.6) 9.7 (3.5)
BMI (kg/m2)† 423 25.7 (23.0,29.7) 24.9 (22.4,28.8)
Sum of skinfold thickness (mm) 360 81.9 (27.0) 78.3 (29.1)
25(OH)D at 14 weeks (nmol/L) 445 45.1 (16.2) 44.4 (15.2)
25(OH)D at 34 weeks (nmol/L) 432 42.8 (20.0) 66.3 (19.8)
n (%)
Nulliparous 427 99 (46.3) 91 (42.7)
Educational qualification > A level 423 156 (74.3) 163 (76.5)
Current smoker 426 16 (7.5) 12 (5.7)
Strenuous exercise  once a week 390 22 (11.3) 32 (16.4)
Values are n (%), mean (SD), or median (interquartile range [IQR]). P difference 25(OH)D at 34 weeks, cholecalciferol supplemented versus placebo
group, p< 0.001.
Table 1B.Whole-Body Minus Head DXA Characteristics of the MAVIDOS Babies by Sex for Whom DXA and RXRA Methylation Data Are
Available
Boys (n¼ 202) Girls (n¼ 173) p difference between boys and girls
Gestational age (weeks) 40.2 (1.3) 40.1 (1.4) 0.22
BA (cm2) 306.5 (34.8) 295.8 (33.8) 0.003
BMC (g) 63.1 (10.7) 59.9 (10.5) 0.004
aBMD (g/cm2) 0.205 (0.018) 0.202 (0.020) 0.100
p values <0.05 are in bold.
BA¼bone area; BMC¼bone mineral content; aBMD¼ areal bone mineral density.
Table 1C.Whole-Body Minus Head DXA Characteristics of the MAVIDOS Babies by Maternal Randomization Group for Whom DXA and
RXRA Methylation Data Are Available
Placebo (N¼ 185)
Cholecalciferol
1000 IU/day (N¼ 190)
p difference between maternal
randomization group
Gestational age (weeks) 40.1 (1.4) 40.2 (1.2) 0.23
BA (cm2) 299.4 (36.7) 303.6 (32.6) 0.24
BMC (g) 61.2 (10.9) 62.0 (10.6) 0.46
aBMD (g/cm2) 0.204 (0.019) 0.203 (0.019) 0.93
p values <0.05 are in bold.
BA¼bone area; BMC¼bone mineral content; aBMD¼ areal bone mineral density.
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supplemented groups, as documented in Fig. 3. In the placebo
group (red bars in Fig. 3), RXRA methylation at CpG 11 was
positively associated with BA (b¼ 6.96 cm2 per 10% increase in
methylation, p¼ 0.05). There was also a tendency towards
positive associations between methylation and BA at CpG 5 and
CpG 12. Furthermore, again in the placebo group, methylation at
CpG 5 and CpG 11 was positively associated with offspring BMC
(at CpG 5, b¼ 1.75g per 10% increase in methylation, p¼ 0.03; at
CpG 11, b¼ 2.34g per 10% increase in methylation, p¼ 0.02).
Conversely, in the cholecalciferol-supplemented group (bluebars
in Fig. 3), no statistically signiﬁcant associations were found
betweenmethylation at CpG5, CpG11, and CpG 12 and offspring
neonatal DXA bone outcomes (Supplementary Table 5).
ENCODE functional analysis
The DMR itself resides within the upstream CpG island shore
region (within 2 kb) of the RXRA 5’CpG island. ENCODE
consortium data were interrogated for functional evidence
within this location.(17) This investigation revealed that the
region of interest within the RXRA locus contains a cluster of
DNase I hypersensitive sites (DHS, a general regulatory marker,
often found within regulatory elements such as promoters and
enhancers(18)), identiﬁed in 84 cell lines out of 125 (see
Supplementary Fig. 2, with examples from the chorion and
osteoblast cell lines highlighted). Furthermore, signiﬁcant
enrichment of the enhancer-related H3K4me1 histone mark
Fig. 2. Difference in RXRA DNA methylation at each CpG site between cholecalciferol 1000 IU/day supplemented group and placebo group (expressed
as SDs). Each bar is the outcome of a separate linear regression (mean difference and 95% CI).
Table 2. RXRA DNA Methylation in Cholecalciferol 1000 IU/day Supplemented and Placebo Groups
n
% methylation
Cholecalciferol 1000 IU/day
% methylation
Placebo
Mean diff. %
methylation 95% CI p difference q difference
RXRA CpG 5 447 46.7 (8.2) 48.7 (9.7) 1.98 3.65, 0.32 0.02 0.06
RXRA CpG 11 446 58.3 (7.5) 58.9 (8.1) 0.67 2.12, 0.78 0.36 0.36
RXRA CpG 12 446 66.1 (5.8) 66.9 (6.6) 0.84 1.99, 0.31 0.15 0.225
CpG 5 represents CpG 1 to CpG 5; CpG 11 represents CpG 8 to CpG 11. p values < 0.05 are in bold. q values were obtained using the Simes method.
Difference in methylation¼mean (cholecalciferol 1000 IU/day) – mean (placebo).
Table 3. RXRA DNA Methylation in Cholecalciferol 1000 IU/day Supplemented and Placebo Groups, Stratiﬁed by Season: Winter Births
(December to May) and Summer Births (June to November)
Winter births (Dec to May) Summer births (June to Nov)
CpG Mean diff. % methylation 95% CI p q Mean diff. % methylation 95% CI p q
RXRA CpG 5 0.27 (2.27, 2.82) 0.83 0.83 3.69 (5.92,1.45) 0.001 0.004
RXRA CpG 11 1.51 (0.73, 3.76) 0.18 0.55 2.38 (4.29,0.47) 0.02 0.01
RXRA CpG 12 0.79 (1.00, 2.58) 0.38 0.58 2.13 (3.60,0.65) 0.005 0.007
Difference in methylation¼mean (cholecalciferol 1000 IU/day) – mean (placebo). p values<0.05 are in bold. q values were obtained using the Simes
method.
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across a range of tissue types was found both across and
within 250 bp of the DMR (Supplementary Fig. 2). Enhancer
loci may show dynamic DNA methylation indicative of
transcription factor interaction within these functional
regions.(19) Consistent with this, genome segmentations
from ENCODE (displaying chromatin state segmentations
from six cell lines) predict weak enhancer activity or an
open chromatin cis regulatory element at the RXRA DMR
(yellow region in Supplementary Fig. 2) at the RXRA DMR.
Finally, ENCODE transcription factor binding data demonstrate
signiﬁcant binding within the RXRA DMR. The numbers of
transcription factor binding sites found at the RXRA DMR in the
ENCODE database vary between cell types. For example, in the
cell line, MCF-7, which is highly responsive to estrogen and
TSH,(20) three transcription factors bind with high afﬁnity at the
RXRA DMR (MYC, CTCF, and POL2RA). In summary, these
ﬁndings suggest the RXRA DMR as a region of signiﬁcant
functional activity across a range of cell types, with evidence of
strong DNAse I hypersensitivity sites, weak enhancer or cis
regulatory element activity, and transcription factor binding.
RXRA methylation and gene expression in vitamin
D-treated placental villous fragments
To experimentally investigate the inﬂuence of vitamin D on
RXRAmethylation in perinatal tissue (placenta), we collected six
placentas from healthy term pregnancies, outside the MAVIDOS
trial (with full ethics approval, REC 11/sc/0323), within 30min of
delivery. Placental villous fragments were cultured in buffered
solution with or without 20mM 25-hydroxyvitamin D [25(OH)D]
(for detailed methods, see Supplementary Material). The
placental samples were snap frozen and stored at 80°C.
DNA was extracted, and DNA methylation was measured using
the Illumina EPIC 850k array (Illumina, San Diego, CA, USA). CpGs
in which DNA methylation was altered were identiﬁed using a
Wilcoxon signed-rank test. RNAwas also extracted, and stranded
RNA sequencing was performed; differentially expressed genes
following 25(OH)D treatment were identiﬁed. In human
placental villous fragments, 25(OH)D treatment altered DNA
methylation at six CpG sites in the RXRA gene: decreased at four
CpG sites (-0.80% to2.67%, p¼ 0.04 and p¼ 0.02, respectively)
and increased in two (1.10% to 1.41%, p¼ 0.04 and p¼ 0.01,
respectively), as shown in Supplementary Table 6. Through RNA
sequencing, RXRA gene expression was shown to increase
following 25(OH)D treatment (log fold change 0.50, p¼ 0.04).
Discussion
In this study we have demonstrated, to our knowledge for the
ﬁrst time in a randomized controlled trial setting, that
supplementation with cholecalciferol in pregnancy is associated
with reduced methylation at speciﬁc regions near to the RXRA
promoter in fetal DNA derived from the umbilical cord of the
offspring. Percentage methylation levels measured by pyrose-
quencingwere lower in the cholecalciferol supplemented group
than the placebo group (statistically signiﬁcantly at the cluster of
CpG sites represented by CpG 5), raising the possibility of site-
speciﬁcity for a molecular interaction between 25(OH)D in
pregnancy and DNA methylation.(21)
Table 4. Relationships Between Perinatal Methylation in Umbilical Cord at CpG Sites Within the RXRA Region of Interest and Bone
Indices at Birth (Measured by DXA, Whole Body Minus Head)
BA, (cm2) BMC, (g) aBMD, (g/cm2 )
RXRA CpG b (95% CI) p b (95% CI) p b (95% CI) p
CpG 5 4.18 (0.16, 8.20) 0.04 1.50 (0.27, 2.74) 0.02 0.002 (0.000, 0.004) 0.05
CpG 11 2.77 (1.93, 7.48) 0.25 0.84 (0.61, 2.30) 0.26 0.001 (0.002, 0.004) 0.47
CpG 12 2.85 (3.19, 8.88) 0.35 0.62 (1.25, 2.49) 0.52 0.000 (0.003, 0.003) 0.91
Associations are adjusted for sex and treatment group. b coefﬁcients and 95% CIs have been multiplied by 10 and therefore represent the change
associated with a 10% increase in methylation. p values <0.05 are in bold.
BA¼bone area; BMC¼bone mineral content; aBMD¼ areal bone mineral density.
Fig. 3. Associations between RXRAmethylation at CpG 5, CpG 11, and CpG 12 and whole-body minus head bone area (cm2), bone mineral content (g),
BMD (g/cm2), adjusted for sex, by treatment group (placebo [red bars] or 1000 IU cholecalciferol daily [blue bars]). Outcomes expressed per 10% increase
in methylation.
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These results are consistent with our previous observational
ﬁndings in the SWS, in which a negative association was found
between an estimate of maternal-free 25(OH)-vitamin D and
RXRA methylation at CpG 4/5,(5) measured using the
Sequenom MassARRAY EpiTYPER (Sequenom Laboratories,
San Diego, CA, USA). Additionally, the associations between
RXRA methylation and neonatal bone indices in the placebo
group replicated those observed previously in the SWS;
conversely, in the present study, the direction of the
association appeared to be reversed (albeit not reaching
statistical signiﬁcance) in the group whose mothers were
supplemented with cholecalciferol. It is interesting that the
methylation difference between treatment and placebo
groups in the present study was greater in summer than
winter births. The increase in 25(OH)D from baseline to
34 weeks was markedly greater for summer than winter
deliveries, although the absolute difference between groups
at 34 weeks was marginally less in summer than in winter,
suggesting that greater increases in 25(OH)D across pregnancy
might facilitate methylation differences consequent to vitamin
D supplementation. However, given that RXRA interacts with
several different nuclear hormone receptors, such as thyroid
hormone receptor and PPAR-gamma, activation of either of
which tends to have detrimental effects on bone, it is possible
that we are seeing the net result of a complex series of
interrelationships at this molecular level, with exogenous
vitamin D perhaps modifying the balance in RXRA interaction
between receptor types, resulting in heterogeneous associa-
tions between RXRA methylation and bone indices. Such
considerations may be relevant both to the skeletal and to the
seasonal differences we observed, although ultimately these
questions must remain the focus of future research. Interest-
ingly, we observed no consistent associations between
maternal 25(OH)D in late pregnancy and RXRA methylation,
but these measures were in different tissues, 6 weeks apart,
and we were able to directly test whether treatment of
perinatal tissue (placenta) with vitamin D would alter RXRA
methylation. Thus, consistent with the ﬁndings from the
MAVIDOS trial, in a small study of human placental villous
fragments RXRA methylation appeared to be lowered at
several CpG sites by the addition of 25(OH)D, and indeed RXRA
expression upregulated overall, suggesting a speciﬁc role for
the vitamin D–RXRA interaction.
Although the exact nature of the mechanistic underpinnings
of our ﬁndings remains to be elucidated, there are several routes
by which maternal 25(OH)D status might inﬂuence perinatal
RXRA methylation. As previously stated, RXRA forms a hetero-
dimer with several nuclear hormones known to inﬂuence bone
metabolism, including 1,25(OH)2-vitamin D, perhaps implying
that maternal 25(OH)D status plays a permissive role in the
transcriptional regulation of the RXRA gene. Studies have shown
that vitamin D may interact with the epigenome on multiple
levels,(17,22–25) and our evaluation of public data from ENCODE
suggests that methylation at the studied CpG sites is likely to
have functional relevance, with evidence for DNase I hypersen-
sitive regions, enhancer activity, and transcription factor
binding. Furthermore, this suggested function within the
DMR, which itself resides within the shore region of the 5’
CpG island. This location has been associated with inﬂuence on
gene expression.(26) Epigenome-wide association studies
(EWASs) have also provided some insight into the actions of
vitamin D on DNA methylation. A small EWAS of DNA
methylation in severely vitamin-D-deﬁcient African-American
adolescents demonstrated associations between vitamin D
status and methylation in several genes, including genes
involved in vitamin D metabolism such as the 24 and 25-
hydroxylase genes. In the context of low serum vitamin D levels,
the promoter of CYP2R1 may become methylated; this is
reversible on exposure to vitamin D.(27) Other studies have
assessed the DNAmethylation in CYP enzymes, which are part of
the vitamin D metabolism pathway, and found a relationship
between methylation of the genes CYP2R1 (25-hydroxylase) and
CYP24A1 (24-hydroxylase) and variations in circulating 25(OH)D
levels.(28) However, a study using the ALSPAC (Avon Longitu-
dinal Study of Parents and Children) cohort and the Norwegian
Mother and Child Cohort (MoBa) inwhichmaternal 25(OH)Dwas
measured in midpregnancy, demonstrated no convincing
associations between maternal 25(OH)D status and DNA
methylation in the umbilical cord blood (as opposed to umbilical
cord tissue in our study) of 1416 newborn babies using Illumina
450k DNA methylation array analysis, thereby covering 473,731
CpG DNA methylation sites.(29) The authors suggested that to
further identify associations, larger consortium studies, ex-
panded genomic coverage, and the investigation of alternative
cell types or 25(OH)D status at different gestational time points
might be needed.
The data presented are from a placebo-controlled, double-
blind, randomized trial, using the gold standards of pyrose-
quencing to determine CpG site-speciﬁc DNA methylation and
DXA to assess bone mass. However, the limitations of our
study must be considered. First, we have analyzed methylation
in cells from whole umbilical cord; therefore, it is possible that
the differential methylation we observed arose from different
component cells in individual samples (eg, ﬁbroblasts and
epithelial cells). The difference in DNA methylation between
treatment and control groups may thus partly reﬂect different
proportions of cells and their cell-speciﬁc DNA methylation.
However, any unaccounted cell heterogeneity may represent
proportional differences that are related to the observed
phenotypic outcomes,(30,31) and so potentially on the causal
pathway. Second, owing to stipulations made during the
ethics approval process, participants with baseline 25(OH)D
concentrations less than 25 nmol/L or greater than 100 nmol/L
could not be included. In addition, the study population did
not include many women who were of nonwhite ethnicity,
which again would affect the generalizability of our ﬁndings to
multiethnic populations. Third, DXA assessment in neonates
presents some difﬁculties, including the low absolute BMC of
newborn babies and their tendency to move. However, the
validity of DXA in small animals, of comparable size to
neonates, has been documented(32) and appropriate DXA
software was used. Fourth, some participants were taking
vitamin D supplements in addition to the study drug, though
supplement use was recorded at interview and did not differ
between the treatment groups. Fifth, though we have
previously excluded the presence of any SNPs at the CpG
sites of interest at the RXRA locus by sequencing, we did not
have information permitting exclusion of a genetic cis or
trans-effect of local or distant SNPs, respectively. These could
inﬂuence either associations between vitamin D supplemen-
tation and RXRA methylation, or inﬂuence both RXRA
methylation and the child’s bone phenotype. Sixth, we did
not have measurements of 25(OH)D in umbilical cord blood;
thus we were not able to directly assess a potential mediating
role for 25(OH)D for RXRA methylation in the same organ at
the same time. Finally, it should be noted that the analysis is
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post hoc and that methylation outcomes were not prespeci-
ﬁed in the original analysis plan, and so will require replication
in further intervention studies.
In conclusion, we have shown in a randomized controlled trial
thatmaternal supplementationwithcholecalciferol from14-weeks’
gestation to delivery leads to lower levels of DNA methylation at
the RXRA promoter in umbilical cord. This informs our understand-
ing of early life mechanisms underpinning maternal vitamin D
status, epigenetic change, and bone development, and may
suggest a novel biomarker for a child’s future bone health.
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